What type of study is this?

This is a Phase 3 study (also classified as: Human Clinical Trial).

October 9, 2025Indian Journal of DermatologyOpen Access

Topical Tofacitinib for Atopic Dermatitis – Outcomes from Randomized Phase 3 Clinical Trial: First Approval

View Full Paper

Ask AI

Bookmark

Authors

ACAlok ChaturvediPurdue University West Lafayette HZHemant ZaveriIntas Pharmaceuticals (India)DPDev PatelUniversity of Illinois Chicago

Discussion

Member takes

Implication

Phase 3 trial reports improved EASI scores in patients with atopic dermatitis, indicating potential for JAK inhibitors. Tofacitinib ointment may offer a safe alternative to pimecrolimus cream.

Key Points

Tofacitinib significantly improved EASI scores in mild-to-moderate atopic dermatitis patients after 4 weeks.
Patients treated with tofacitinib had comparable results to those on pimecrolimus, achieving EASI 50%, 75%, and 90% improvement.
Trial used a randomized, multicenter phase 3 design involving 184 patients receiving either tofacitinib or pimecrolimus.
Demonstrates safety and efficacy in atopic dermatitis treatment, highlighting the need for more JAK inhibitor options.

Cite This Study

Chaturvedi et al. (2025) studied this question.

synapsesocial.com/papers/68e77f09d1c187e1c108fcee https://doi.org/10.4103/ijd.ijd_197_24

View Full Paper

Ask AI

Bookmark

Implication

Phase 3 trial reports improved EASI scores in patients with atopic dermatitis, indicating potential for JAK inhibitors. Tofacitinib ointment may offer a safe alternative to pimecrolimus cream.

Topical Tofacitinib for Atopic Dermatitis – Outcomes from Randomized Phase 3 Clinical Trial: First Approval

Discussion

Member takes

Implication

Key Points

Cite This Study

Topical Tofacitinib for Atopic Dermatitis – Outcomes from Randomized Phase 3 Clinical Trial: First Approval

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider